These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose https://orlandosvks680868.amoblog.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-60915045